X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DR. REDDYS LAB - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DR. REDDYS LAB GLENMARK PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 14.4 34.3 42.0% View Chart
P/BV x 3.8 3.4 113.1% View Chart
Dividend Yield % 0.3 0.8 39.5%  

Financials

 GLENMARK PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
DR. REDDYS LAB
Mar-17
GLENMARK PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs9933,397 29.2%   
Low Rs7292,560 28.5%   
Sales per share (Unadj.) Rs325.5856.5 38.0%  
Earnings per share (Unadj.) Rs39.378.0 50.4%  
Cash flow per share (Unadj.) Rs48.7139.9 34.8%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.20.7 34.6%  
Book value per share (Unadj.) Rs159.2739.8 21.5%  
Shares outstanding (eoy) m282.17165.74 170.2%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.63.5 76.1%   
Avg P/E ratio x21.938.2 57.4%  
P/CF ratio (eoy) x17.721.3 83.1%  
Price / Book Value ratio x5.44.0 134.4%  
Dividend payout %5.125.7 19.8%   
Avg Mkt Cap Rs m242,991493,632 49.2%   
No. of employees `00013.022.7 57.2%   
Total wages/salary Rs m16,40831,068 52.8%   
Avg. sales/employee Rs Th7,083.96,259.0 113.2%   
Avg. wages/employee Rs Th1,265.41,369.8 92.4%   
Avg. net profit/employee Rs Th855.1569.7 150.1%   
INCOME DATA
Net Sales Rs m91,857141,961 64.7%  
Other income Rs m3741,715 21.8%   
Total revenues Rs m92,230143,676 64.2%   
Gross profit Rs m20,36724,722 82.4%  
Depreciation Rs m2,64410,266 25.8%   
Interest Rs m2,373634 374.3%   
Profit before tax Rs m15,72415,537 101.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,965 129.1%   
Profit after tax Rs m11,08812,921 85.8%  
Gross profit margin %22.217.4 127.3%  
Effective tax rate %24.319.1 127.5%   
Net profit margin %12.19.1 132.6%  
BALANCE SHEET DATA
Current assets Rs m68,74696,837 71.0%   
Current liabilities Rs m27,02784,199 32.1%   
Net working cap to sales %45.48.9 510.2%  
Current ratio x2.51.2 221.2%  
Inventory Days Days8573 115.9%  
Debtors Days Days9698 97.8%  
Net fixed assets Rs m24,132102,552 23.5%   
Share capital Rs m282829 34.0%   
"Free" reserves Rs m44,643121,792 36.7%   
Net worth Rs m44,925122,621 36.6%   
Long term debt Rs m45,3635,449 832.5%   
Total assets Rs m117,639218,165 53.9%  
Interest coverage x7.625.5 29.9%   
Debt to equity ratio x1.00 2,272.3%  
Sales to assets ratio x0.80.7 120.0%   
Return on assets %11.46.2 184.2%  
Return on equity %24.710.5 234.2%  
Return on capital %19.112.9 148.4%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m56,15281,670 68.8%   
Fx outflow Rs m8,08426,355 30.7%   
Net fx Rs m48,06855,315 86.9%   
CASH FLOW
From Operations Rs m6,57421,444 30.7%  
From Investments Rs m-7,124-18,404 38.7%  
From Financial Activity Rs m5,432-3,692 -147.1%  
Net Cashflow Rs m1,992-1,144 -174.2%  

Share Holding

Indian Promoters % 48.3 25.5 189.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.4 127.8%  
FIIs % 34.4 35.3 97.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   56,727 75,885 74.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS